{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:47:12Z","timestamp":1793170032240,"version":"4.5.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 diabetes mellitus remain unknown. This study aimed to evaluate the effects of the two novel antidiabetic agents on cognitive dysfunction by comparing the rates of dementia between SGLT2I and DPP4I users.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    This was a population-based cohort study of type 2 diabetes mellitus patients treated with SGLT2I and DPP4I between January 1, 2015 and December 31, 2019 in Hong Kong. Exclusion criteria were &amp;lt;1-month exposure or exposure to both medication classes, or prior diagnosis of dementia or major neurological\/psychiatric diseases. Primary outcomes were new-onset dementia, Alzheimer's, and Parkinson's. Secondary outcomes were all-cause, cardiovascular, and cerebrovascular mortality.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 13,276 SGLT2I and 36,544 DPP4I users (total\n                    <jats:italic>n<\/jats:italic>\n                    = 51,460; median age: 66.3 years old [interquartile range (IQR): 58\u201376], 55.65% men) were studied (follow-up: 472 [120\u2013792] days). After 1:2 matching (SGLT2I:\n                    <jats:italic>n<\/jats:italic>\n                    = 13,283; DPP4I:\n                    <jats:italic>n<\/jats:italic>\n                    = 26,545), SGLT2I users had lower incidences of dementia (0.19 vs. 0.78%,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.0001), Alzheimer's (0.01 vs. 0.1%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0047), Parkinson's disease (0.02 vs. 0.14%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0006), all-cause (5.48 vs. 12.69%,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.0001), cerebrovascular (0.88 vs. 3.88%,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.0001), and cardiovascular mortality (0.49 vs. 3.75%,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.0001). Cox regression showed that SGLT2I use was associated with lower risks of dementia (hazard ratio [HR]: 0.41, 95% confidence interval [CI]: [0.27\u20130.61],\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.0001), Parkinson's (HR:0.28, 95% CI: [0.09\u20130.91],\n                    <jats:italic>P<\/jats:italic>\n                    = 0.0349), all-cause (HR:0.84, 95% CI: [0.77\u20130.91],\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.0001), cardiovascular (HR:0.64, 95% CI: [0.49\u20130.85],\n                    <jats:italic>P<\/jats:italic>\n                    = 0.0017), and cerebrovascular (HR:0.36, 95% CI: [0.3\u20130.43],\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.0001) mortality.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The use of SGLT2I is associated with lower risks of dementia, Parkinson's disease, and cerebrovascular mortality compared with DPP4I use after 1:2 ratio propensity score matching.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2021.747620","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T02:57:38Z","timestamp":1634785058000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":104,"title":["Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Jonathan V.","family":"Mui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Sai Kit","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teddy Tai Loy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Hou In","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shek Long","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham Ka Chung","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Tak","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fendo.2018.00261","article-title":"Depressive symptoms, co-morbidities, and glycemic control in Hong Kong Chinese elderly patients with Type 2 diabetes mellitus","volume":"9","author":"Fung","year":"2018","journal-title":"Front Endocrinol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12902-021-00751-4","article-title":"Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning","volume":"21","author":"Lee","year":"2021","journal-title":"BMC Endocr Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/ckj\/sfaa200","article-title":"Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study","volume":"14","author":"Kovesdy","year":"2021","journal-title":"Clin Kidney J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000513782","article-title":"Cardiovascular and renal outcomes in patients with type-2 diabetes and chronic kidney disease identified in a United States administrative claims database: a population cohort study","volume":"145","author":"Folkerts","year":"2021","journal-title":"Nephron."},{"key":"B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1534734617699318","article-title":"Influence of epidemiologic and patient behavior-related predictors on amputation rates in diabetic patients: systematic review and meta-analysis","volume":"16","author":"Shin","year":"2017","journal-title":"Int J Low Extrem Wounds."},{"key":"B6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2213-8587(19)30405-X","article-title":"Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression","volume":"8","author":"van Sloten","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","article-title":"Cognitive decline and dementia in diabetes\u2013systematic overview of prospective observational studies","volume":"48","author":"Cukierman","year":"2005","journal-title":"Diabetologia."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: the Rotterdam Study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1210\/er.2007-0034","article-title":"Cognitive dysfunction and diabetes mellitus","volume":"29","author":"Kodl","year":"2008","journal-title":"Endocr Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2337\/dc16-1229","article-title":"Cognitive dysfunction in older adults with diabetes: what a clinician needs to know","volume":"40","author":"Munshi","year":"2017","journal-title":"Diabetes Care."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMc1311765","article-title":"Glucose levels and risk of dementia","volume":"369","author":"Crane","year":"2013","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2174\/1567205016666191023110712","article-title":"Glycemic control is related to cognitive dysfunction in elderly people with Type 2 diabetes mellitus in a rural chinese population","volume":"16","author":"Liu","year":"2019","journal-title":"Curr Alzheimer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.diabres.2019.07.004","article-title":"Oral diabetes medication and risk of dementia in elderly patients with type 2 diabetes","volume":"154","author":"Kim","year":"2019","journal-title":"Diabetes Res Clin Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00125-017-4541-7","article-title":"HbA(1c), diabetes and cognitive decline: the english longitudinal study of ageing","volume":"61","author":"Zheng","year":"2018","journal-title":"Diabetologia."},{"key":"B16","doi-asserted-by":"publisher","first-page":"107668","DOI":"10.1016\/j.neuropharm.2019.107668","article-title":"DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling","volume":"157","author":"Chen","year":"2019","journal-title":"Neuropharmacology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0228750","DOI":"10.1371\/journal.pone.0228750","article-title":"The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation","volume":"15","author":"Ide","year":"2020","journal-title":"PLoS One."},{"key":"B18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e037056","DOI":"10.1002\/alz.037056","article-title":"Effects of an SGLT2 inhibitor on cognition in diabetes involving amelioration of deep cortical cerebral blood flow autoregulation and pericyte function","volume":"16","author":"Wang","year":"2020","journal-title":"Alzheimer's Dementia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol Appl Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/CPAA.S164785","article-title":"12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. a randomized clinical trial in the elderly with Type-2 diabetes mellitus","volume":"10","author":"Perna","year":"2018","journal-title":"Clin Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00592-020-01605-6","article-title":"Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study","volume":"58","author":"Lee","year":"2021","journal-title":"Acta Diabetol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"105473","DOI":"10.1016\/j.phrs.2021.105473","article-title":"Anticoagulant or antiplatelet use and severe COVID-19 disease: a propensity score-matched territory-wide study","volume":"165","author":"Zhou","year":"2021","journal-title":"Pharmacol Res."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323668","article-title":"Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study","author":"Zhou","year":"2020","journal-title":"Gut."},{"key":"B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/jcm8010028","article-title":"Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: a real-world population-based cohort study","volume":"8","author":"Kim","year":"2018","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3233\/JAD-201535","article-title":"The association between second-line oral antihyperglycemic medication on types of dementia in Type 2 diabetes: a nationwide real-world longitudinal study","volume":"81","author":"Kim","year":"2021","journal-title":"J Alzheimers Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/gerona\/glu032","article-title":"Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment","volume":"69","author":"Rizzo","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"154265","DOI":"10.1016\/j.metabol.2020.154265","article-title":"Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis","volume":"109","author":"Zhou","year":"2020","journal-title":"Metabolism."},{"key":"B33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.neubiorev.2016.03.005","article-title":"Diabetes and Alzheimer's disease crosstalk","volume":"64","author":"Baglietto-Vargas","year":"2016","journal-title":"Neurosci Biobehav Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/archneur.62.10.1556","article-title":"Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease","volume":"62","author":"Kivipelto","year":"2005","journal-title":"Arch Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1111\/dom.13841","article-title":"Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-7-S1-A58","article-title":"Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis","author":"Pinto","year":"2015","journal-title":"Diabetol Metab Syndr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","article-title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease","volume":"72","author":"Kosaraju","year":"2013","journal-title":"Neuropharmacology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/bab.1319","article-title":"Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders","volume":"63","author":"Shaikh","year":"2016","journal-title":"Biotechnol Appl Biochem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","article-title":"Type 3 diabetes and its role implications in Alzheimer's disease","volume":"21","author":"Nguyen","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bbadis.2016.08.018","article-title":"Is Alzheimer's disease a Type 3 diabetes? A critical appraisal","volume":"1863","author":"Kandimalla","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/jphp.12148","article-title":"Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease","volume":"65","author":"Kosaraju","year":"2013","journal-title":"J Pharm Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.exger.2009.12.004","article-title":"Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice","volume":"45","author":"D'Amico","year":"2010","journal-title":"Exp Gerontol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl Peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer's disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol Neurobiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","article-title":"The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease","volume":"123","author":"Isik","year":"2017","journal-title":"Diabetes Res Clin Pract."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/alz.12161","article-title":"Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status","volume":"16","author":"Wu","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/ph13110379","article-title":"Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on Alzheimer's disease and ischemia-related brain injury","volume":"13","author":"Wici\u0144ski","year":"2020","journal-title":"Pharmaceuticals."},{"key":"B47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mds.27836","article-title":"Understanding the links between cardiovascular disease and Parkinson's disease","volume":"35","author":"Potashkin","year":"2020","journal-title":"Mov Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2796.2006.01687.x","article-title":"Cardiovascular disease and Alzheimer's disease: common links","volume":"260","author":"Stampfer","year":"2006","journal-title":"J Intern Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JPD-191900","article-title":"The Association between Type 2 diabetes mellitus and Parkinson's disease","volume":"10","author":"Cheong","year":"2020","journal-title":"J Parkinsons Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care."},{"key":"B51","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/dc10-1922","article-title":"Diabetes and risk of Parkinson's disease","volume":"34","author":"Xu","year":"2011","journal-title":"Diabetes Care."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/brain\/awab015","article-title":"Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease","volume":"144","author":"Jeong","year":"2021","journal-title":"Brain."},{"key":"B54","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/j.parkreldis.2015.09.034","article-title":"Cognitive impairment in Parkinson's disease and dementia with Lewy bodies","volume":"22","author":"Aarsland","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.parkreldis.2003.12.005","article-title":"Dementia with Lewy bodies and Parkinson's disease","volume":"10","author":"McKeith","year":"2004","journal-title":"Parkinsonism Relat Disord."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.12688\/f1000research.11725.1","article-title":"Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies","volume":"6","author":"Weil","year":"2017","journal-title":"F1000Res."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.747620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T02:57:40Z","timestamp":1634785060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.747620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":56,"alternative-id":["10.3389\/fcvm.2021.747620"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.747620","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"article-number":"747620"}}